Recro Pharma Inc. (REPH) Rating Reiterated by HC Wainwright
Recro Pharma Inc. (NASDAQ:REPH)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday. They presently have a $19.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 137.50% from the stock’s current price.
Several other research firms have also recently weighed in on REPH. Roth Capital set a $24.00 price target on shares of Recro Pharma and gave the company a “buy” rating in a report on Monday. Brean Capital reiterated a “buy” rating and issued a $28.00 price target on shares of Recro Pharma in a report on Thursday, August 11th. Zacks Investment Research upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Janney Montgomery Scott assumed coverage on shares of Recro Pharma in a report on Monday, August 29th. They issued a “buy” rating and a $21.00 price target for the company. Finally, Aegis assumed coverage on shares of Recro Pharma in a report on Monday, November 14th. They issued a “buy” rating and a $21.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $19.13.
Recro Pharma (NASDAQ:REPH) opened at 8.00 on Tuesday. Recro Pharma has a 1-year low of $5.59 and a 1-year high of $12.50. The firm’s market capitalization is $97.30 million. The company has a 50-day moving average of $7.71 and a 200-day moving average of $8.33.
Several hedge funds have recently made changes to their positions in the company. Stonepine Capital Management LLC raised its stake in shares of Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock worth $3,408,000 after buying an additional 191,796 shares in the last quarter. Granite Point Capital Management L.P. purchased a new stake in Recro Pharma during the third quarter valued at about $636,000. Acadian Asset Management LLC purchased a new stake in Recro Pharma during the third quarter valued at about $140,000. Northern Trust Corp purchased a new stake in Recro Pharma during the third quarter valued at about $128,000. Finally, BlackRock Institutional Trust Company N.A. raised its stake in Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares during the period. 52.28% of the stock is currently owned by institutional investors and hedge funds.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.